Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

62.46
+0.13000.21%
Pre-market: 61.99-0.4700-0.75%07:24 EDT
Volume:1.80M
Turnover:112.48M
Market Cap:12.09B
PE:416.40
High:62.89
Open:62.06
Low:61.45
Close:62.33
Loading ...

Sector Update: Health Care Stocks Flat to Lower Premarket Thursday

MT Newswires Live
·
16 Jan

Incyte, Syndax Receive FDA Approval for Niktimvo to Treat Chronic Graft-Versus-Host Disease

MT Newswires Live
·
16 Jan

Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes

Dow Jones
·
16 Jan

Incyte, Syndax announce FDA approval for Niktimvo vial sizes

TIPRANKS
·
16 Jan

BRIEF-Incyte And Syndax Announce U.S. Food And Drug Administration (FDA) Approval Of Niktimvo™ (Axatilimab-Csfr) 9 mg And 22 mg Vial Sizes

Reuters
·
16 Jan

Incyte Corp - Niktimvo Expected to Be Available in U.S. in Early February

THOMSON REUTERS
·
16 Jan

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (Axatilimab-Csfr) 9 Mg and 22 Mg Vial Sizes

THOMSON REUTERS
·
16 Jan

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

Zacks
·
14 Jan

Incyte’s Strategic Challenges: Navigating Post-Jakafi Growth Gap and Limited Business Development Capacity

TIPRANKS
·
14 Jan

Incyte Stock: Hold Rating Amid Patent Cliff Concerns and Awaited Clinical Milestones

TIPRANKS
·
14 Jan

Incyte Corp. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

Dow Jones
·
14 Jan

Top Research Reports for Apple, Alphabet & Cisco

Zacks
·
11 Jan

INCY vs. VRTX: Which Stock Is the Better Value Option?

Zacks
·
11 Jan

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
09 Jan

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
09 Jan

Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
09 Jan

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
09 Jan

Incyte (INCY) Receives a Hold from Truist Financial

TIPRANKS
·
08 Jan

Incyte’s Strategic Balancing Act: Promising Drug Prospects Amid Competitive and Intellectual Property Challenges

TIPRANKS
·
07 Jan

Incyte price target raised to $75 from $74 at RBC Capital

TIPRANKS
·
07 Jan